A sixth vaccine from China starts human clinical trial. Anhui Zhifei is a business unit of Chinese publicly listed Chongqing Zhifei Biological Products.
Chinese firm gets approval to begin human testing for potential coronavirus vaccine
The new vaccine from Anhui Zhifei is a recombinant protein vaccine.
All the previous 5 vaccines from China under human clinical trial are either the adenovirus vector vaccine or inactivated vaccine. This sixth vaccine gives China a wide variety of vaccine technology to fight the Covid-19.
Chinese firm gets approval to begin human testing for potential coronavirus vaccine
- China has approved a coronavirus vaccine candidate developed by Chongqing Zhifei Biological Products' unit to begin human testing, the company said in a filing on Tuesday (June 23).
- The potential vaccine, co-developed by Anhui Zhifei Longcom Bioplharmaceutica and the Institute of Microbiology of the Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials.
The new vaccine from Anhui Zhifei is a recombinant protein vaccine.
- A recombinant protein vaccine involves using a specific piece of the virus, such as the spike protein of the antigen, to trigger a protective immune response, according to United States' National Institutes of Health. They are known to provide very strong protection and is very safe, though booster shots might be needed to get ongoing protection.
- Some common recombinant vaccines include ones against Hepatitis B, influenza, whooping cough and Human papillomavirus or HPV.
- The Chinese recombinant protein vaccine uses the spike protein of the novel coronavirus to elicit an immunological response, the institute said. It has been tested on mice and rhesus macaques and shown to produce highly potent virus neutralizing antibodies.
All the previous 5 vaccines from China under human clinical trial are either the adenovirus vector vaccine or inactivated vaccine. This sixth vaccine gives China a wide variety of vaccine technology to fight the Covid-19.